Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 05/15/25 | 10-Q | Quarterly report [Sections 13 or 15(d)] |
|
   |
107 |
| 05/15/25 | 8-K | Current report |
|
|
10 |
| 05/13/25 | ARS | Annual Report to Security Holders |
|
173 | |
| 05/13/25 | DEF 14A | Definitive proxy statements |
|
|
61 |
| 04/30/25 | PRE 14A | Preliminary proxy statement not related to a contested matter or merger/acquisition |
|
|
61 |
| 03/31/25 | EFFECT | Notice of Effectiveness |
|
1 | |
| 03/31/25 | S-8 | Securities to be offered to employees in employee benefit plans |
|
10 | |
| 03/31/25 | POS AM | Post-effective amendment to a registration statement that is not immediately effective upon filing |
|
82 | |
| 03/31/25 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] |
|
|
198 |
| 03/31/25 | POSASR | Post-effective Amendment to an automatic shelf registration statement |
|
88 |
